Table 1.
Clinical characteristics of two patients with Parkinson’s disease who had severe coldness of the lower limbs.
| Characteristics | Patient 1 | Patient 2 |
|---|---|---|
| Age/sex | 75/M | 80/F |
| Disease duration, years | 4 | 10.7 |
| Hoehn-Yahr stage | 4 | 3 (on periods) 4 (off periods) |
| Clinical phenotype | Akinesia | Akinesia |
| Wearing-off | + | + |
| Hallucinations | + | - |
| Dyskinesia | - | - |
| MMSE during cold limbs | 27 *a | 27 |
| Autonomic symptoms | C, OD, S | C, U |
| Nature of the cold limbs | ||
| Duration | NA | 2.4 yr |
| Time | Everyday, off periods | Everyday, off periods |
| Presence during summer time | + | + |
| Regions | Both proximal and distal LL | Both distal LL |
| With pain | Frequent | Often |
| Other sensory symptoms | Tightness | Tightness |
| Decreased by physical warm stimulations | + | + |
| Daily treatment on development of cold limbs (dose/day) | ||
| Levodopa | 500 mg | 300 mg |
| Pergolide | - | 0.5 mg |
| Selegiline | 7.5 mg | - |
| Entacapone | - | 600 mg |
| Zonisamide | 50 mg | - |
| Dose modification within 12 months before cold limbs (time) | ZNS initiated (25 mg/d) and increased (50 mg/d) | Entacapone increased (600 mg/d) 6 months |
| Neuroleptics | - | - |
| Pain medication | Pregabalin (150 mg/d) | Poultice |
| Treatment | ||
| Antiparkinsonian drugs | Rotigotine initiated and increased (36 mg/d) | RP initiated and increased (8 mg/d); rotigotine initiated and increased (18 mg/d) |
| Neuroleptics | - | - |
| Outcome | ||
| UPDRS Part 3 | 21 | 11 |
| Hoehn-Yahr stage | 3 (on periods) 3 (off periods) | 3 (on periods) 4 (off periods) |
| Cold limbs | Mildly reduced | Mildly reduced |
| Pain | Mildly reduced | Disappeared |
PD, Parkinson's disease; Hs, hallucinations; UPDRS, Unified Parkinson's Disease Rating Scale; LL, lower limbs; MMSE, Mini-Mental State Examination; C, constipation; U, urinary urgency; OD, orthostatic diziness; S, sweating abnormalities; m, months; d, day; ND, not done.
*a: examinated in September 2014 when cold limbs were present.